Navigation Links
Publication of Supplementary Prospectus
Date:4/29/2008

d May, One Bunhill Row, London EC1Y 8YY.

- This announcement is an advertisement and not a prospectus and investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information contained in the prospectus and the supplementary prospectus published by shire limited in connection with the proposed scheme. The prospectus was published on 16 April 2008 and made available on shire's website and is available for inspection at the UK listing authority's document viewing facility. The supplementary prospectus has been published today and will be made available on shire's website and is available for inspection at the uk listing authority's document viewing facility.

Notes to editors

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

This announcement does not constitute an offer or invitation to purchase securities.

Terms used but not defined herein have the meanings given to them in the Prospectus.

Morgan Stanley & Co International plc is acting for Shire and Shire Limited and no one else in connection wit
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
2. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
3. United BioSource Acquires Leading Publication Planning Software and Services Company
4. Publication Addresses Misconceptions About Emergency Contraception
5. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
6. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
7. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
8. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
9. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
10. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
11. Research by Case Western Reserve University, VA earns cover of prestigious science publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... BOSTON, MA (PRWEB) September 30, 2014 ... company, SoundConnect announces four new-hosted collaboration ... innovative bundles deliver high quality conferencing experiences for ... collaboration packages to choose from, businesses have optimized ... bundled solutions include audio only minutes ...
(Date:10/1/2014)... Industry leaders from retail ... around the theme, ,Commercial Opportunities in the Era of ... Elsevier , a world-leading provider of scientific, ... a gathering of some of the industry,s most prominent ... today and in the future. The Elsevier ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... - 2014 Summary Global Markets Direct,s, ... - 2014, provides an overview of the Pacific ... This report provides comprehensive information on the ... LLC,s, complete with comparative analysis at various stages, ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader ... genetic test built upon research from their published P.A.I.N. ... provide physicians with an objective way to understand theirs ... between individuals. With this new test, physicians will be ... predisposition that will affect their pain tolerance. , The ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... Group,plc (AIM: PRG) announces the appointment of Melissa ... will be,responsible for leading the International Business Development ... business development position within,Kendle International leading a Global ... within business development in the CRO sector with ...
... Quigley,Corporation (Nasdaq: QGLY ) today issued an update ... Peripheral Neuropathy by its wholly owned,subsidiary, Quigley Pharma, ... that over 100 subjects have been,enrolled, 52 subjects have ... the Phase IIB study designed to evaluate the safety ...
... Will Begin Promotion in October At U.S. Psychiatric ... Pharmaceuticals,Inc. announced today that it has acquired the ... from Shire,plc. EQUETRO(R) is a treatment for ... Disorder -- a condition where patients experience,extended periods ...
Cached Biology Technology:Premier Research Appoints Melissa Jones as Vice President, International Business Development 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 2Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy 3Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R) 2
(Date:9/30/2014)... marijuana, new research, involving mice and published in the ... Leukocyte Biology , suggests that just because you ... because a team of Italian scientists have found that ... to the immune system. This damage may result in ... sclerosis, inflammatory bowel disease and rheumatoid arthritis in adulthood. ...
(Date:9/30/2014)... 2014  Spectra Automation, a trusted supplier ... and power generation industries, announced today the ... an easy-to-use and cost-effective data collection, analysis ... laboratories. Most upstream process ... systems. Accessing and consolidating data from these ...
(Date:9/29/2014)... the exposure to tar tended to be lower for ... Similarly, exposure to nicotine tended to be lower. , ... in several countries around the world. Previous studies have ... the smoke of these cigarettes are lower than those ... in the smoke are not necessarily linked to a ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... resistant to Crown Rot a disease that costs Australian ... year. Crown Rot, which is a chronic problem throughout ... Fusarium . Dr Chunji Liu and his CSIRO Plant ... scan over 2400 wheat lines and 1000 barley lines from ...
... 27, 2009 -- Worldwide demand for a safe and ... the forefront of sustainability discussions; however many research programs ... of traditional public or formula grants. Researchers are now ... and international plant breeding programs. Stakeholders from public ...
... Oregon State University researchers shows that those in poverty in ... be eating, but face tough choices between eating well and ... Rosenberger, both professors of anthropology at OSU, examined the "double ... interviews with 76 low-income households in two rural Benton County ...
Cached Biology News:How do we fund plant breeding? 2How do we fund plant breeding? 3Poor in rural Oregon face 'double binds' when getting food 2Poor in rural Oregon face 'double binds' when getting food 3
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Biology Products: